These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 32987955)

  • 21. Assessment of PD-1 positive cells on initial and secondary resected tumor specimens of newly diagnosed glioblastoma and its implications on patient outcome.
    Miyazaki T; Ishikawa E; Matsuda M; Akutsu H; Osuka S; Sakamoto N; Takano S; Yamamoto T; Tsuboi K; Matsumura A
    J Neurooncol; 2017 Jun; 133(2):277-285. PubMed ID: 28447277
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low-dose valganciclovir as preemptive therapy for cytomegalovirus infection occurring in allogeneic stem cell transplant recipients.
    Palladino M; Laurenti L; Chiusolo P; Piccioni P; Innocenti I; Tarnani M; Sorà F; Sica S; Leone G
    Acta Haematol; 2010; 123(4):230-4. PubMed ID: 20424437
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Valganciclovir as preemptive therapy for cytomegalovirus in cytomegalovirus-seronegative liver transplant recipients of cytomegalovirus-seropositive donor allografts.
    Singh N; Wannstedt C; Keyes L; Mayher D; Tickerhoof L; Akoad M; Wagener MM; Cacciarelli TV
    Liver Transpl; 2008 Feb; 14(2):240-4. PubMed ID: 18236404
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
    Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Indefinite cytomegalovirus prophylaxis with valganciclovir after lung transplantation.
    Hecker M; Hecker A; Askevold I; Kuhnert S; Reichert M; Guth S; Mayer E; Slanina H; Schüttler CG; Seeger W; Padberg W; Mayer K
    Transpl Infect Dis; 2019 Oct; 21(5):e13138. PubMed ID: 31278878
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ganciclovir concentrations in the cerebral extracellular space after valganciclovir treatment; a case study.
    Peredo I; Helldén A; Wolmer-Solberg N; Pohanka A; Stragliotto G; Rahbar A; Ståhle L; Bellander BM; Söderberg-Nauclér C
    BMJ Case Rep; 2015 Dec; 2015():. PubMed ID: 26670887
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma.
    Brandes AA; Gil-Gil M; Saran F; Carpentier AF; Nowak AK; Mason W; Zagonel V; Dubois F; Finocchiaro G; Fountzilas G; Cernea DM; Chinot O; Anghel R; Ghiringhelli F; Beauchesne P; Lombardi G; Franceschi E; Makrutzki M; Mpofu C; Urban HJ; Pichler J
    Oncologist; 2019 Apr; 24(4):521-528. PubMed ID: 30266892
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?
    Jain A; Orloff M; Kashyap R; Lansing K; Betts R; Mohanka R; Menegus M; Ryan C; Bozorgzadeh A
    Transplant Proc; 2005 Sep; 37(7):3182-6. PubMed ID: 16213344
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial.
    Rapp M; Grauer OM; Kamp M; Sevens N; Zotz N; Sabel M; Sorg RV
    Trials; 2018 May; 19(1):293. PubMed ID: 29801515
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Onset of valganciclovir resistance in two infants with congenital cytomegalovirus infection.
    Garofoli F; Lombardi G; Angelini M; Campanini G; Zavattoni M; Baldanti F
    Int J Infect Dis; 2020 Sep; 98():150-152. PubMed ID: 32615325
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic analysis of patients who underwent gross total resection of newly diagnosed glioblastoma.
    Matsuda M; Kohzuki H; Ishikawa E; Yamamoto T; Akutsu H; Takano S; Mizumoto M; Tsuboi K; Matsumura A
    J Clin Neurosci; 2018 Apr; 50():172-176. PubMed ID: 29396060
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytomegalovirus disease among donor-positive/recipient-negative lung transplant recipients in the era of valganciclovir prophylaxis.
    Mitsani D; Nguyen MH; Kwak EJ; Silveira FP; Vadnerkar A; Pilewski J; Crespo M; Toyoda Y; Bermudez C; Clancy CJ
    J Heart Lung Transplant; 2010 Sep; 29(9):1014-20. PubMed ID: 20598582
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Extended Efficacy of Low-Dose Valganciclovir for Prevention of Cytomegalovirus Disease in Intermediate-Risk Kidney Transplant Recipients: Two-Year Follow-Up.
    Halim MA; Gheith OA; Makkeya Y; Nagib AM; Atta AF; Emam M; Yehia A; Said T; Nair P; Al-Otaibi T
    Exp Clin Transplant; 2019 Jun; 17(3):339-343. PubMed ID: 30674240
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Less renal allograft fibrosis with valganciclovir prophylaxis for cytomegalovirus compared to high-dose valacyclovir: a parallel group, open-label, randomized controlled trial.
    Reischig T; Kacer M; Hruba P; Hermanova H; Hes O; Lysak D; Kormunda S; Bouda M
    BMC Infect Dis; 2018 Nov; 18(1):573. PubMed ID: 30442095
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and Safety of a Weight-based Dosing Regimen of Valganciclovir for Cytomegalovirus Prophylaxis in Pediatric Solid-organ Transplant Recipients.
    Pappo A; Peled O; Berkovitch M; Bilavsky E; Rom E; Amir J; Krause I; Yarden-Bilavsky H; Scheuerman O; Ashkenazi-Hoffnung L
    Transplantation; 2019 Aug; 103(8):1730-1735. PubMed ID: 31343571
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of adjuvant or salvage radiosurgery in the management of unresected residual or progressive glioblastoma multiforme in the pre-bevacizumab era.
    Niranjan A; Kano H; Iyer A; Kondziolka D; Flickinger JC; Lunsford LD
    J Neurosurg; 2015 Apr; 122(4):757-65. PubMed ID: 25594327
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cytomegalovirus and glioblastoma; controversies and opportunities.
    Lawler SE
    J Neurooncol; 2015 Jul; 123(3):465-71. PubMed ID: 25682092
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytomegalovirus disease and infection in lung transplant recipients in the setting of planned indefinite valganciclovir prophylaxis.
    Wiita AP; Roubinian N; Khan Y; Chin-Hong PV; Singer JP; Golden JA; Miller S
    Transpl Infect Dis; 2012 Jun; 14(3):248-58. PubMed ID: 22385394
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cytomegalovirus and Glioblastoma: A Review of the Biological Associations and Therapeutic Strategies.
    Yang T; Liu D; Fang S; Ma W; Wang Y
    J Clin Med; 2022 Sep; 11(17):. PubMed ID: 36079151
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impact of pre-transplant valganciclovir on early cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation.
    Wilhelm K; Chemaly R; Saliba R; Gulbis A; Saunders I; Cool R; Ferguson J; Westmoreland M; Rondon G; Kebriaei P
    J Oncol Pharm Pract; 2014 Aug; 20(4):257-62. PubMed ID: 24022408
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.